



National Human  
Genome Research  
Institute



National  
Institutes of  
Health



U.S. Department  
of Health and  
Human Services


# Genomics in the Genome-Wide Association Era: What's Next for Translation?

U.S. Department of Health and Human Services  
National Institutes of Health  
National Human Genome Research Institute

Teri A. Manolio, M.D., Ph.D.  
Director, Office of Population Genomics  
Senior Advisor to the Director, NHGRI,  
for Population Genomics

October 22, 2008

ond quarter 2008



# 2007: The Year of GWA Studies


**BREAKTHROUGH OF THE YEAR**

## Human Genetic Variation

Equipped with faster, cheaper technologies for sequencing DNA and assessing variation in genomes on scales ranging from one to millions of bases, researchers are finding out how truly different we are from one another

THE UNVEILING OF THE HUMAN GENOME ALMOST 7 YEARS AGO cast the first faint light on our complete genetic makeup. Since then, each new genome sequenced and each new individual studied has illuminated our genomic landscape in ever more detail. In 2007, researchers came to appreciate the extent to which our genomes differ from person to person and the implications of this variation for deciphering the genetics of complex diseases and personal traits.

Less than a year ago, the big news was triangulating variation between us and our primate cousins to get a better handle on genetic changes along the evolutionary tree that led to humans. Now, we have moved from asking what in our DNA makes us human to striving to know what in my DNA makes me me.



**What makes us unique.** Changes in the number and order of genes (A–D) add variety to the human genome.

# Diseases and Traits with Published GWA Studies (n = 72, 10/14/08)

- Macular Degeneration
- Exfoliation Glaucoma
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Bladder Cancer
- Neuroblastoma
- Melanoma
- *TP53* Cancer Predispos'n
- Chr. Lymph. Leukemia
- Inflamm. Bowel Disease
- Celiac Disease
- Gallstones
- Irritable Bowel Syndrome
- QT Prolongation
- Coronary Disease
- Coronary Spasm
- Atrial Fibrillation/Flutter
- Stroke
- Subarachnoid Hemorrhage
- Hypertension
- Hypt. Diuretic Response
- Peripheral Artery Disease
- Lipids and Lipoproteins
- Warfarin Dosing
- Ximelegatran Adv. Resp.
- Parkinson Disease
- Amyotrophic Lat. Sclerosis
- Multiple Sclerosis
- MS Interferon- $\beta$  Response
- Prog. Supranuclear Palsy
- Alzheimer's Disease in  $\epsilon 4+$
- Cognitive Ability
- Memory
- Hearing
- Restless Legs Syndrome
- Nicotine Dependence
- Methamphetamine Depend.
- Neuroticism
- Schizophrenia
- Sz. Iloperidone Response
- Bipolar Disorder
- Family Chaos
- Narcolepsy
- Rheumatoid Arthritis
- RA Anti-TNF Response
- Syst. Lupus Erythematosus
- Sarcoidosis
- Psoriasis
- HIV Viral Setpoint
- Childhood Asthma
- Type 1 Diabetes
- Type 2 Diabetes
- Diabetic Nephropathy
- End-St. Renal Disease
- Obesity, BMI, Waist, IR
- Height
- Osteoporosis
- Osteoarthritis
- Male Pattern Baldness
- F-Cell Distribution
- Fetal Hgb Levels
- C-Reactive Protein
- ICAM-1
- Total IgE Levels
- Uric Acid Levels, Gout
- Protein Levels
- Vitamin B12 Levels
- Recombination Rate
- Pigmentation

## STATISTICS AND MEDICINE

# Drinking from the Fire Hose — Statistical Issues in Genomewide Association Studies

David J. Hunter, M.B., B.S., and Peter Kraft, Ph.D.

Related article, page 443

The past 3 months have seen the publication of a series of articles highlighting the need for guessing which genes are likely to harbor variants associated with disease. The main problem with this strategy is that, because of the

*“There have been few, if any, similar bursts of discovery in the history of medical research...”*

and in this issue of the *Journal*, coronary artery disease (reported by Samani et al., pages 443–453). These genomewide association studies have been able to examine interpatient differences in inherited genetic variability at an unprecedented level of resolution, thanks to the development of microarrays, or chips, capable of as-

sociated with disease. Some of these associations have been found in regions not even known to harbor genes, such as the 8q24 region, in which multiple variants have been found to be associated with prostate cancer.<sup>2</sup> Such findings promise to open up new avenues of research, through both the discovery of new genes rele-

lated to the disease. Some of these associations have been found in regions not even known to harbor genes, such as the 8q24 region, in which multiple variants have been found to be associated with prostate cancer.<sup>2</sup> Such findings promise to open up new avenues of research, through both the discovery of new genes rele-

generate P values as small as  $10^{-7}$ . In addition, most variants identified recently have been associated with modest relative risks (e.g., 1.3 for heterozygotes and 1.6 for homozygotes), and many true associations are not likely to exceed P values as extreme as  $10^{-7}$  in an initial study. On the other hand, a “statistically significant” finding

# What is a Genome-Wide Association Study?


- Method for interrogating all 10 million variable points across human genome
- Variation inherited in groups, or blocks, so not all 10 million points have to be tested
- Blocks are shorter (so need to test more points) the less closely people are related
- Technology now allows studies in unrelated persons, assuming 5,000 – 10,000 base pair lengths in common (300,000 – 1,000,000 markers)

# DNA on Chromosome 7

GAAATAATTAATGTTTTCTTCCTTCTCCTATTTTGTCCTTACTTCAATTTATTTATTTATTATTAATATTATTATTTTTTGGAG  
ACGGAGTTT **C/A**CTCTTGTTGCCAACCTGGAGTGCAGTGGCGTGATCTCAGCTCACTGCACACTCCGCTTTCCTGGTT  
TCAAGCGATTCTCCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGTCACACACCACCACGCCCGGCTAATTTTTGTA  
TTTTTAGTAGAGTTGGGGTTTCACCATGTTGGCCAGACTGGTCTCGAACTCCTGACCTTGTGATCCGCCAGCCTCTGC  
CTCCCAAAGAGCTGGGATTACAGGCGTGAGCCACCGCGCTCGGCCCTTTCATCAATTTCTACAGCTTGTTTTCTTTG  
CCTGGACTTTACAAGTCTTACCTTGTTCTGC **C/T**TCAGATATTTGTGTGGTCTCATTCTGGTGTGCCAGTAGCTAAAAAT  
CCATGATTTGCTCTCATCCACTCCTGTTGTTCACTCCTCTTATCTGGGGTCCAC **A/C**TATCTCTCGTGATTGCATTCT  
GATCCCAGTACTTAGCATGTGCGTAACAACCTCTGCCTCTGCTTCCAGGCTGTTGATCCCGTGCTGTTTCATGCCTCA  
GAAAAATGCATTGTAAGTTAAATTATTAAGATTTTAAATATAGGAAAAAAGTAAGCAAACATAAGGAACAAAAAGGAA  
AGAACATGTATTCTAATCCATTATTTATTATACAATTAAGAAATTTGGAAACTTTAGATTACACTGCTTTTAGAGATGGAGA  
TGTAAGTCTTTTTACTCTTTACAAAATACATGTGTTAGCAATTTGGGAAGAATAGTAACTCACCCGAACAGT **G/T**AA  
TGTGA **TATGTC**CTTACTAGAGGAAAGAAGGCACTTGAAAAACATCTCTAAACCGTATAAAAACAATTACATCATAATG  
ATGAAAACCCAGGAATTTTTTTAGAAAACATTACCAGGGCTAATAACAAAGTAGAGCCACATGTCATTTATCTTCCCTT  
TGTGTCTGTGTGAGAATTCTAGAGTTATATTTGTACATAGCATGGAAAAATGAGAGGCTAGTTTATCAACTAGTTCATTTT  
TAAAAGTCTAACACATCCTAGGTATAGGTGAACTGTCCTCCTGCCAATGTATTGCACATTTGTGCCAGATCCAGCATA  
GGGTATGTTTGCCATTTACAACGTTTATGTCTTAAGAGAGCAAAATATGAAGAGCAAACAGTGCATGCTGGAGAGAG  
AAAGCTGATACAAATATAAA **T/G**AAACAATAATTGGAAA **AATTGA**AAACTACTCATTTTCTAAATTACTCATGATTTTTC  
CTAGAATTTAAGTCTTTTAATTTTTGATAAATCCCAATGTGACAGAAAGATAAGTATTAGTGATGGTATGAGTAATTAATATC  
TGTTATATAATATTCATTTTCATAGTGAAGAAATAAAATAAAGGTTGTGATGATTGTTGATTATTTTTTCTAGAGGGGTTG  
TCAGGGAAAGAAATTGCTTTTT

SNPs 1 / 300 bases


# Mapping the Relationships Among SNPs



Christensen and Murray, *N Engl J Med* 2007; 356:1094-97.



# Chromosome 9p21 Region Associated with MI



Samani N et al, *N Engl J Med* 2007; 357:443-453.

# Distances Among East Coast Cities


	Boston	Provi- dence	New York	Phila- delphia	Balti- more
Providence	59				
New York	210	152			
Philadelphia	320	237	86		
Baltimore	430	325	173	87	
Washington	450	358	206	120	34

# Distances Among East Coast Cities


	Boston	Provi- dence	New York	Phila- delphia	Balti- more
Providence	59				
New York	210	152			
Philadelphia	320	237	86		
Baltimore	430	325	173	87	
Washington	450	358	206	120	34



# Distances Among East Coast Cities




# Distances Among East Coast Cities




# Distances Among East Coast Cities

Boston Providence New York Philadelphia Baltimore Washington



# Mapping the Relationships Among SNPs



Christensen and Murray, *N Engl J Med* 2007; 356:1094-97.

# One Tag SNP May Serve as Proxy for Many

Block 1

Block 2

SNP1 SNP2 SNP3 SNP4 SNP5 SNP6 SNP7 SNP8

CAGATCGCTGGATGAATCGCATCTGTAAGCAT

CGGATTGCTGCATGGATCGCATCTGTAAGCAC

CAGATCGCTGGATGAATCGCATCTGTAAGCAT

CAGATCGCTGGATGAATCCATCAGTACGCAT

CGGATTGCTGCATGGATCCATCAGTACGCAT

CGGATTGCTGCATGGATCCATCAGTACGCAC



# One Tag SNP May Serve as Proxy for Many

Block 1

Block 2

SNP1	SNP2	SNP3	SNP4	SNP5	SNP6	SNP7	SNP8
<u>A</u>	<u>C</u>	<u>G</u>	<u>A</u>	<u>G</u>	<u>T</u>	<u>A</u>	<u>T</u>
<u>G</u>	<u>T</u>	<u>C</u>	<u>G</u>	<u>G</u>	<u>T</u>	<u>A</u>	<u>C</u>
<u>A</u>	<u>C</u>	<u>G</u>	<u>A</u>	<u>G</u>	<u>T</u>	<u>A</u>	<u>T</u>
<u>A</u>	<u>C</u>	<u>G</u>	<u>A</u>	<u>C</u>	<u>A</u>	<u>C</u>	<u>T</u>
<u>G</u>	<u>T</u>	<u>C</u>	<u>G</u>	<u>C</u>	<u>A</u>	<u>C</u>	<u>T</u>
<u>G</u>	<u>T</u>	<u>C</u>	<u>G</u>	<u>C</u>	<u>A</u>	<u>C</u>	<u>C</u>

# One Tag SNP May Serve as Proxy for Many

Block 1

Block 2

SNP3

SNP5

SNP6

SNP7

SNP8

↓  
G  
C  
G  
G  
C  
C

↓  
G  
G  
G  
C  
C  
C

↓  
T  
T  
T  
A  
A  
A

↓  
A  
A  
A  
C  
C  
C

↓  
T  
C  
T  
T  
T  
C

# One Tag SNP May Serve as Proxy for Many

Block 1

Block 2

SNP3



G

C

G

G

C

C

SNP6



T

T

T

A

A

A

SNP8



T

C

T

T

T

C

# One Tag SNP May Serve as Proxy for Many

The diagram illustrates how a single tag SNP can serve as a proxy for many other haplotypes. It shows six haplotypes, each with three positions. The first position is grouped into 'Block 1', the second into 'Block 2', and the third into 'Singleton'. The frequency of each haplotype is listed on the right.

Block 1	Block 2	Singleton	Frequency
	<u>G</u> TT		35%
	<u>C</u> TC		30%
	<u>G</u> TT		10%
	<u>G</u> AT		8%
	<u>C</u> AT		7%
	<u>C</u> AC		6%
other haplotypes			4%



[www.hapmap.org](http://www.hapmap.org)

Vol 437|27 October 2005|doi:10.1038/nature04226

nature

Vol 449|18 October 2007|doi:10.1038/nature06258

nature

*Nature* 2007; 449:851-61.

ARTICLES

# A second generation human haplotype map of over 3.1 million SNPs


The International HapMap Consortium\*

We describe the Phase II HapMap, which characterizes over 3.1 million human single nucleotide polymorphisms (SNPs) genotyped in 270 individuals from four geographically diverse populations and includes 25–35% of common SNP variation in the populations surveyed. The map is estimated to capture untyped common variation with an average maximum  $r^2$  of between 0.9 and 0.96 depending on population. We demonstrate that the current generation of commercial genome-wide genotyping products captures common Phase II SNPs with an average maximum  $r^2$  of up to 0.8 in African and up to 0.95 in non-African populations, and that potential gains in power in association studies can be obtained through imputation. These data also reveal novel aspects of the structure of linkage disequilibrium. We show that 10–30% of pairs of individuals within a population share at least one region of extended genetic identity arising from recent ancestry and that up to 1% of all common variants are untaggable, primarily because they lie within recombination hotspots. We show that recombination

# A HapMap for More Efficient Association Studies: Goals


- Use just the density of SNPs needed to find associations between SNPs and diseases
- Do not miss chromosomal regions with disease association
- Produce a tool to assist in finding genes affecting health and disease
- Use more SNPs for complete genome coverage of populations of recent African ancestry populations due to shorter LD

# Progress in Genotyping Technology



Courtesy S. Chanock, NCI

# Continued Progress in Genotyping Technology



Courtesy S. Gabriel, Broad/MIT



# Association of Alleles and Genotypes of rs1333049 with Myocardial Infarction

	C N (%)	G N (%)	$\chi^2$ (1df)	P-value
Cases	2,132 (55.4)	1,716 (44.6)	55.1	$1.2 \times 10^{-13}$
Controls	2,783 (47.4)	3,089 (52.6)		


Allelic Odds Ratio = 1.38

# Association of Alleles and Genotypes of rs1333049 with Myocardial Infarction

	C N (%)	G N (%)	$\chi^2$ (1df)	P-value
Cases	2,132 (55.4)	1,716 (44.6)	55.1	$1.2 \times 10^{-13}$
Controls	2,783 (47.4)	3,089 (52.6)		
Allelic Odds Ratio = 1.38				


	CC N (%)	CG N (%)	GG N (%)	$\chi^2$ (2df)	P-value
Cases	586 (30.5)	960 (49.9)	378 (19.6)	59.7	$1.1 \times 10^{-14}$
Controls	676 (23.0)	1,431 (48.7)	829 (28.2)		
Heterozygote Odds Ratio = 1.47					
Homozygote Odds Ratio = 1.90					

# P Values of GWA Scan for Age-Related Macular Degeneration




Klein et al, *Science* 2005; 308:385-389.

# Nicotine Dependence among Smokers




Bierut LJ et al, *Hum Molec Genet* 2007; 16:24-35.

# Genome-Wide Scan for Type 2 Diabetes in a Scandinavian Cohort




<http://www.broad.mit.edu/diabetes/scandinav/type2.html>

# $-\text{Log}_{10} P$ Values for SNP Associations with Myocardial Infarction




Samani N et al., *N Engl J Med* 2007; 357:443-53.

# Association Signal for Coronary Artery Disease on Chromosome 9




Samani N et al., *N Engl J Med* 2007; 357:443-53.

# Region of Chromosome 1 Showing Strong Association with Inflammatory Bowel Disease







# Published GWA Reports, 3/2005 - 9/2008




# Published GWA Reports, 3/2005 - 9/2008




# Published GWA Reports, 3/2005 - 9/2008



# Published GWA Reports, 3/2005 - 9/2008



# Published GWA Reports, 3/2005 - 9/2008



# NHGRI Catalog of GWA Studies:

<http://www.genome.gov/gwastudies/>

genome.gov  
National Human Genome Research Institute  
National Institutes of Health

Search

Home | About NHGRI | Newsroom | Staff

Research | Grants | Health | Policy & Ethics | Educational Resources | Careers & Training

Home > About NHGRI > About the Office of the Director > Office of Population Genomics > **A Catalog of Published Genome-Wide Association Studies**

Print Version

## A Catalog of Published Genome-Wide Association Studies

### Search By:

First Author:

Publication:

Disease/Trait:

Search


Clear Query

First Author/Date/ Journal/Study	Disease/Trait	Initial Sample Size	Replication Sample Size	Region	Gene	Strongest SNP-Risk Allele	Risk Allele Frequency in Controls	P- value	OR per copy or B-coefficient for heterozygote and [95% CI]	Platfo [SNPs pas
Amos April 03, 2008 <i>Nat Genet</i> <a href="#">Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at15q251</a>	Lung cancer	1,154 cases, 1,137 controls	2,724 cases, 3,694 controls	15q25.1	<i>CHRNA3</i>	rs8034191-G	NR	3 x 10 <sup>-18</sup>	1.30 [1.15-1.47]	Illumina [317,498]
				1q23.2	<i>CRP</i>	rs2808630-G	NR	7 x 10 <sup>-6</sup>	1.22 [1.10-1.35]	
				3q28	<i>IL1RAP</i>	rs7626795-G	NR	8 x 10 <sup>-6</sup>	1.16 [1.05-1.28]	
Hung April 03, 2008 <i>Nature</i> <a href="#">A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25</a>	Lung cancer	1,926 cases, 2,522 controls	2,513 cases, 4,752 controls	15q25.1	<i>CHRNA3, CHRNA5, CHRNB4</i>	rs8034191-C	0.34	5 x 10 <sup>-20</sup>	1.21 [1.11-1.31]	Illumina [310,023]
Spinola January 16, 2007 <i>Cancer Lett</i> <a href="#">Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene</a>	Lung cancer	338 Italian lung adenocarcinoma cases, 335 Italian controls	265 Norwegian non-small lung carcinoma cases, 356 Norwegian controls	NA	NA	NA	NA	NS	NA	Affymetrix [116,204] (pooled)

# NHGRI GWA Catalog - Objectives


- Identify and track all GWA publications attempting to assay  $\geq 100,000$  SNPs
- Extract key information regarding associations
- Provide widely as scientific resource, including downloadable datafile
- Seek commonalities across associations genome-wide rather than disease by disease
- Describe approach clearly so others can replicate or expand upon it
- Maintain consistency in approach
- Adapt to evolving technologies: CNVs?

# Functional Classification of 782 Index SNPs Associated with Complex Traits





# Functional Classification of 782 Index SNPs and 4,623 Index + Linked SNPs



# Functional Classes (%) of Linked and Index SNPs vs Randomly-Drawn HapMap SNPs

Functional Class	Index	Linked	HapMap	P-value*
Missense	4.7	1.3	0.6	$2 \times 10^{-6}$
Synonymous	1.4	0.7	0.5	0.05
Intronic	43.5	47.5	37.5	$6 \times 10^{-38}$
5' UTR	0.3	0.3	0.1	0.05
3' UTR	1.4	1.0	0.9	0.23
miRTS	0.8	0.5	0.3	0.12
5' (2kb)	2.8	2.0	1.1	$2 \times 10^{-7}$
3' (0.5kb)	2.6	1.8	1.2	$3 \times 10^{-4}$
Intergenic	45.3	47.0	58.1	$4 \times 10^{-59}$

\* Multiple comparisons correction  $p_{\text{threshold}} = 0.006$ .

# Functional Classes (%) of Linked and Index SNPs vs Randomly-Drawn HapMap SNPs

Functional Class	Index	Linked	HapMap	P-value*
Missense	4.7	1.3	0.6	$2 \times 10^{-6}$
Synonymous	1.4	0.7	0.5	0.05
Intronic	43.5	47.5	37.5	$6 \times 10^{-38}$
5' UTR	0.3	0.3	0.1	0.05
3' UTR	1.4	1.0	0.9	0.23
miRTS	0.8	0.5	0.3	0.12
5' (2kb)	2.8	2.0	1.1	$2 \times 10^{-7}$
3' (0.5kb)	2.6	1.8	1.2	$3 \times 10^{-4}$
Intergenic	45.3	47.0	58.1	$4 \times 10^{-59}$

\* Multiple comparisons correction  $p_{\text{threshold}} = 0.006$ .

# Lessons Learned from Initial GWA Studies

## Signals in Previously Unsuspected Genes

Macular Degeneration	<i>CFH</i>
Coronary Disease	<i>CDKN2A/2B</i>
Childhood Asthma	<i>ORMDL3</i>
Type II Diabetes	<i>CDKAL1</i>
Crohn's Disease	<i>ATG16L1</i>

---

# Lessons Learned from Initial GWA Studies

## Signals in Previously Unsuspected Genes

Macular Degeneration	<i>CFH</i>
Coronary Disease	<i>CDKN2A/2B</i>
Childhood Asthma	<i>ORMDL3</i>
Type II Diabetes	<i>CDKAL1</i>
Crohn's Disease	<i>ATG16L1</i>

## Signals in Gene "Deserts"

Prostate Cancer	8q24
Crohn's Disease	5p13.1, 1q31.2, 10p21

---

# Lessons Learned from Initial GWA Studies

## Signals in Previously Unsuspected Genes

Macular Degeneration

*CFH*

Coronary Disease

*CDKN2A/2B*

Childhood Asthma

*ORMDL3*

Type II Diabetes

*CDKAL1*

Crohn's Disease

*ATG16L1*

## Signals in Common

Diabetes, Melanoma

Crohn's Disease

Prostate Cancer

## Signals in Gene "Deserts"

Prostate Cancer

8q24

Crohn's Disease

5p13.1, 1q31.2,  
10p21

# Lessons Learned from Initial GWA Studies

## Signals in Previously Unsuspected Genes

Macular Degeneration

*CFH*

Coronary Disease

*CDKN2A/2B*

Childhood Asthma

*ORMDL3*

Type II Diabetes

*CDKAL1*

Crohn's Disease

*ATG16L1*

## Signals in Common

Diabetes, Melanoma

Crohn's Disease

Prostate Cancer

## Signals in Gene "Deserts"

Prostate Cancer

8q24

Breast, Colorectal  
Cancer; Crohn's

Crohn's Disease

5p13.1, 1q31.2,  
10p21

# Lessons Learned from Initial GWA Studies


Signals in Previously Unsuspected Genes		Signals in Common
Macular Degeneration	<i>CFH</i>	
Coronary Disease	<i>CDKN2A/2B</i>	Diabetes, Melanoma
Childhood Asthma	<i>ORMDL3</i>	Crohn's Disease
Type II Diabetes	<i>CDKAL1</i>	Prostate Cancer
Crohn's Disease	<i>ATG16L1</i>	
Signals in Gene "Deserts"		Signals in Common
Prostate Cancer	8q24	Breast, Colorectal Cancer; Crohn's
Crohn's Disease	5p13.1, 1q31.2, 10p21	
Signals in Common		
Multiple Sclerosis	<i>IL7R</i>	Type 1 Diabetes
Sarcoidosis	<i>C10orf67</i>	Celiac Disease
RA, T1DM	<i>PTPN2, PTPN22</i>	Crohn's



# Lessons Learned from Initial GWA Studies


Signals in Previously Unsuspected Genes		Signals in Common
Macular Degeneration	<i>CFH</i>	
Coronary Disease	<i>CDKN2A/2B</i>	Diabetes, Melanoma
Childhood Asthma	<i>ORMDL3</i>	Crohn's Disease
Type II Diabetes	<i>CDKAL1</i>	Prostate Cancer
Crohn's Disease	<i>ATG16L1</i>	
Signals in Gene "Deserts"		Signals in Common
Prostate Cancer	8q24	Breast, Colorectal Cancer; Crohn's
Crohn's Disease	5p13.1, 1q31.2, 10p21	
Signals in Common		
Multiple Sclerosis	<i>IL7R</i>	Type 1 Diabetes
Sarcoidosis	<i>C10orf67</i>	Celiac Disease
RA, T1DM	<i>PTPN2, PTPN22</i>	Crohn's

# Study Crohn's Disease!



Barrett et al., *Nat Genet* 2008 Jun 29.

1/4/93



“God, Collings, I hate to start a Monday with a case like this.”

Larson, G. *The Complete Far Side*. 2003.

May 1999

**Editorial: Once and Again—Issues Surrounding  
Replication in Genetic Association Studies**

PERSPECTIVE

The Future of Association Studies: Gene-Based Analysis and Replication

B

**Editorial**


**Replication Publication**

Statistical false positive or true disease  
pathway?

John A Todd


*Nat Genet* July 2006

# Replication Strategy for Prostate Cancer Study in CGEMS




Hoover R, *Epidemiology* 2007; 18:13-17.

# GWA Efforts at NHGRI and NIH-wide



FOUNDATION  
HOME | GIVE NOW | CONTACT US | SEARCH



**Genetic Association Information Network (GAIN)**  
**Analysis Workshop III**  
Philadelphia Marriott Downtown  
November 10 - 11, 2008

FOUNDATION  
FOR THE  
National Institutes of Health

Partners for Innovation, Discovery, Life

## Overview

The Genetic Association Information Network (GAIN) is a public-private partnership of the Foundation for the National Institutes of Health, that currently involves the National Institutes of Health (NIH), Pfizer, Affymetrix, Perlegen Sciences, Abbott, and the Eli and Edythe Broad Institute - of MIT and Harvard University. GAIN is taking the next step in the search to understand the genetic factors influencing risk for complex diseases. Through a series of whole genome association studies, using samples from existing case-control studies of patients with common diseases, GAIN will contribute to the identification of genetic pathways that make us more susceptible to these diseases and thus facilitate discovery of new molecular targets for prevention, diagnosis, and treatment.

GAIN announced the selection of six major studies in common diseases for genotyping at our November 2006 GAIN Kickoff Meeting and Analysis Workshop, including studies in ADHD, diabetic nephropathy, major depression, psoriasis, schizophrenia, and bipolar disorder. Since then GAIN has completed genotyping on all six studies and made the resulting phenotype and genotype data available via the GAIN Database in dbGaP at the National Center for Biotechnology Information (NCBI) at NIH ([dbgap](#)). The GAIN Analysis Workshop III will bring together the primary investigators and data analysts from these studies with genetics and data analysis experts from the scientific community to present the results of findings from analysis of the GAIN data, as well as related advances in strategies for analyzing specific genome-wide association data.

# GWA-Related Efforts at NHGRI

## The eMERGE Network electronic Medical Records & Genomics



Web Site  Search Home



Population Architecture using Genomics and Epidemiology (PAGE)

### Part I Overview Information

---

Department of Health and Human Services

#### Participating Organizations

National Institutes of Health (NIH), (<http://www.nih.gov>)

#### Components of Participating Organizations

National Human Genome Research Institute (NHGRI), (<http://www.genome.gov>)

**Title:** Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials – Study Investigators (U01)

#### Announcement Type

New

# GWA-Related Efforts at NHGRI: Training

**Genome-Wide Association Studies for the Rest of Us:  
Adding Genome-Wide Association to Population Studies**

**Multi-IC Symposia on Application of Genomic Technologies to Population-Based  
Studies  
at NIH Institutes and Centers**

**Genetics for Epidemiologists  
Application of Human Genomics to Population Sciences**

**Epidemiology for Researchers Performing Genetic/Genomic Studies**

Natcher Auditorium, NIH Campus

**Bethesda  
July 18, 2008**

## Overview

**Epidemiology for Researchers Performing Genetic/Genomic Studies**, is a short course for investigators and trainees doing research in human genetics, particularly studies employing genomic analyses of samples from human populations. It was conducted by the Office of Population Genomics, NHGRI, on July 18, 2008, in Natcher Auditorium, Building 45, NIH campus.

The course consists of eight lectures and aims at familiarizing researchers studying the human genome with basic principles and potential pitfalls of epidemiology as applied to human genome research. It draws from traditional genetic epidemiology and statistical genetics, but emphasizes the application of genomic technologies to unrelated subjects in human populations. Focus is on the design, conduct, analysis and interpretation of the epidemiologic studies most feasible and appropriate to address the genomic questions of interest.



# NIH-Wide Efforts in Gene Discovery and Translation

NATIONAL INSTITUTES OF HEALTH

## Genes, Environment and Health Initiative (GEI)



U.S. Department of Health and Human Services




U.S. Department of Health and Human Services

### NIH News

National Institutes of Health

#### NIH's Genes, Environment & Health Initiative Adds Six Studies

*Scientists Will Search for Genetic Factors Underlying Stroke, Glaucoma, High Blood Pressure and Other Common Disorders*



**Bethesda, Md.,** Wed., Sept. 24, 2008 — The Genes, Environment and Health Initiative (GEI) of the National Institutes of Health (NIH) today awarded grants, estimated to be up to \$5.5 million over two years, for six studies aimed at finding genetic factors that influence the risks for stroke, glaucoma, high blood pressure, prostate cancer and other common disorders.

The grantees will use a genome-wide association study to rapidly scan markers across the complete sets of DNA, or genomes, of large groups of people to find genetic variants associated with a particular disease, condition or trait.

"Genome-wide association studies are helping us take major strides towards identifying the genetic variants associated with common diseases," said National Human Genome Research Institute (NHGRI) Acting Director Alan E. Guttmacher, M.D., who is co-chair of the GEI coordinating committee. "This initiative will yield valuable information about the biological pathways that lead to health and disease and about how genetic variants, environmental factors and behavioral choices interact to influence disease risk. Such information is vital to our efforts to develop more personalized approaches to health care."

# NIH-Wide Efforts in Gene Discovery and Translation

## Part I Overview Information

Receipt Date: 10/17/2008

## Part I Overview Information

Receipt Date: 11/25/2008

## Part I Overview Information

Receipt Date: 12/1/2008

Department of Health and Human Services

### Participating Organizations

National Institutes of Health (NIH) (<http://www.nih.gov>)

### Components of Participating Organizations

This FOA is developed as a part of the NIH-wide Genes, Environment, and Health Initiative (GEI). All NIH Institutes and Centers participate in NIH-wide initiatives. This FOA will be administered by the National Cancer Institute (NCI, <http://www.cancer.gov>) on behalf of the NIH (<http://www.nih.gov>)

**Title:** Replication and Fine-Mapping Studies for the Genes Environment and Health Initiative (GEI)(R01)

### Announcement Type

New

Request For Applications (RFA) : RFA-CA-09-003



